Download Files:
Firibastat
$120 – $900
Products Details
Product Description
– Firibastat (QGC001), an orally active brain penetrating proagent of EC33, is a first-in-class brain aminopeptidase A (APA) inhibitor (Ki=200 nM). Firibastat selectively and specifically inhibits conversion of brain angiotensin-II into angiotensin-III and decreases blood pressure in hypertensive rats[1][2].
Web ID
– HY-109058
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Neuroscience-Neuromodulation
Molecular Formula
– C8H20N2O6S4
References
– [1]Ferdinand KC, et al. Efficacy and Safety of Firibastat, A First-in-Class Brain Aminopeptidase A Inhibitor, in Hypertensive Overweight Patients of Multiple Ethnic Origins. Circulation. 2019;140(2):138-146.|[2]Keck M, et al. Orally Active Aminopeptidase A Inhibitor Prodrugs: Current State and Future Directions. Curr Hypertens Rep. 2019;21(7):50. Published 2019 May 21.
CAS Number
– 648927-86-0
Molecular Weight
– 368.51
Compound Purity
– 98.0
SMILES
– O=S(CC[C@H](N)CSSC[C@@H](N)CCS(=O)(O)=O)(O)=O
Clinical Information
– Phase 3
Research Area
– Cardiovascular Disease
Solubility
– H2O : 33.33 mg/mL (ultrasonic)
Target
– Aminopeptidase
Pathway
– Metabolic Enzyme/Protease
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
